EyePoint Pharmaceuticals, Inc.
EYPT
$14.52
$0.836.06%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -90.82% | -43.73% | 109.29% | -17.39% | -30.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.82% | -43.73% | 109.29% | -17.39% | -30.77% |
| Cost of Revenue | 61.92% | 78.00% | 90.85% | 131.66% | 60.41% |
| Gross Profit | -147.48% | -132.34% | -79.47% | -583.26% | -511.62% |
| SG&A Expenses | 11.23% | -3.09% | 3.32% | 16.04% | 23.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.57% | 53.47% | 62.85% | 87.04% | 46.19% |
| Operating Income | -89.40% | -80.13% | -46.57% | -176.62% | -127.45% |
| Income Before Tax | -103.44% | -92.48% | -54.33% | -194.73% | -132.80% |
| Income Tax Expenses | -- | -- | -- | 8.43% | -- |
| Earnings from Continuing Operations | -103.44% | -92.78% | -54.33% | -193.63% | -132.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.44% | -92.78% | -54.33% | -193.63% | -132.80% |
| EBIT | -89.40% | -80.13% | -46.57% | -176.62% | -127.45% |
| EBITDA | -90.01% | -80.46% | -46.40% | -175.66% | -126.42% |
| EPS Basic | -57.88% | -46.67% | -17.06% | -91.78% | -63.94% |
| Normalized Basic EPS | -57.86% | -46.45% | -17.06% | -92.54% | -63.91% |
| EPS Diluted | -57.88% | -46.67% | -17.06% | -91.78% | -63.94% |
| Normalized Diluted EPS | -57.86% | -46.45% | -17.06% | -92.54% | -63.91% |
| Average Basic Shares Outstanding | 28.87% | 31.43% | 31.85% | 53.09% | 42.01% |
| Average Diluted Shares Outstanding | 28.87% | 31.43% | 31.85% | 53.09% | 42.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |